Outcomes and Management of Salmonella Enteritis Following Solid Organ Transplantation
1Internal Medicine, Henry Ford Health System, Detroit, MI, 2Gastroenterology, Henry Ford Health System, Detroit, MI
Meeting: 2022 American Transplant Congress
Abstract number: 1633
Keywords: Bacterial infection, Induction therapy, Infection, Surgical complications
Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)
Session Information
Session Name: All Infections (Excluding Kidney & Viral Hepatitis) IV
Session Type: Poster Abstract
Date: Tuesday, June 7, 2022
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
*Purpose: Evaluate the outcomes of patients who developed salmonella infection post solid organ transplant.
*Methods: A retrospective single-center study was conducted at a tertiary transplant center. Patients 18 years and older who developed salmonella post-solid-organ transplant from 2010 to 2019 were included. Data on demographics, baseline characteristics, and clinical outcomes were collected via manual chart review. Outcomes studied included transplant rejection and mortality within 3 years of salmonella diagnosis and duration of hospitalization.
*Results: A total of 10 patients had salmonella infection within 6 months following solid organ transplantation. This included 3 patients with liver transplant only, 1 with kidney transplant, 2 with simultaneous liver and kidney transplant, 3 with lung transplant, and 1 with heart transplant. There was no acute rejection observed within 3 months following transplant. There was no mortality within 3 years following transplant. Survival at 1 and 3 years was 100% and 90% respectively. 1 died due to unrelated reason. One had rejection 6 months post infection. Univariate analysis comparing patient characteristics including age, gender, race, transplant type, salmonella bacteremia, treatment and type of induction to rejection showed no statistical significance. Interestingly, patients who received thymoglobulin or Basilixamab induction therapy had a statistically significant longer hospital stay (P=0.01 and 0.047 respectively) compared to those that received steroids as an induction therapy (P=0.28).
*Conclusions: Solid organ transplant recipients are at higher risk to develop salmonellosis secondary to immunosuppression. Our study showed that there was no significant increase in the rate of rejection and mortality within the first 3 and 6 months of transplant. Patients who underwent thymoglobulin or Basiliximab immunosuppressive induction were found to have significant increase in their length of hospitalization as compared to those who received steroid immunosuppressive induction.
To cite this abstract in AMA style:
Musleh M, Nimri F, Elbanna A, Jafri S. Outcomes and Management of Salmonella Enteritis Following Solid Organ Transplantation [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/outcomes-and-management-of-salmonella-enteritis-following-solid-organ-transplantation/. Accessed December 3, 2024.« Back to 2022 American Transplant Congress